Dow Jones
39.069,59 +4,29 (+0,01%) Nasdaq
16.920,79 +184,79 (+1,10%) Nikkei 225
38.848,38 -51,64 (-0,13%) EUR/USD
1,0873 +0,0013 (+0,12%) Bitcoin EUR
63.807,94 +536,43 (+0,85%) CMC Crypto 200
1.493,83 +9,63 (+0,65%)
Autolus Therapeutics plc (AUTL)
Dopo ore:
| Chiusura precedente | 3,8700 |
| Aperto | 3,8900 |
| Denaro | 0,0000 x 0 |
| Domanda | 0,0000 x 0 |
| Min-Max giorno | 3,8150 - 3,9350 |
| Intervallo di 52 settimane | 2,0100 - 7,4500 |
| Volume | |
| Media Volume | 1.514.225 |
| Capitalizzazione | 1,043B |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,2100 |
| Prossima data utili | 01 ago 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,69 |
GlobeNewswireCorrection - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat
- GlobeNewswire
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023. Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business updat
- GlobeNewswire
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication on the AUTO1/22 Phase 1 study (CARPALL) in Pediatric B-cell Acute Lymphobl
